KDR and hepatocellular carcinoma: In 2007, the multi-kinase inhibitor sorafenib—targeting VEGFR, PDGFR, and RAF pathways—demonstrated a median overall survival (mOS) of 10.7 months in advanced HCC (SHARP trial), marking the dawn of targeted therapy [83].